News – Page 2 – Alligator Bioscience

2016-10-12

Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013

– Janssen assumes responsibility for all future clinical studies Alligator started dosing in the first clinical phase I dose escalatio ...

2016-07-082022-09-20

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy. ...

2016-05-202022-09-20

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another c ...

2016-04-222022-09-20

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of canc ...

2016-03-302022-09-20

After proofreading minor corrections has been made. Comprehensive income and Financial position are however intact. Complete proposal, item ...

2016-03-042022-09-20

Major shareholders have now submitted their proposals regarding items 8 and 9 in the published notice. Proposal item 8: The number of board ...

2016-02-152022-09-20

The shareholders of Alligator Bioscience AB (publ), Reg. No 556597-8201, are hereby invited to attend the extraordinary shareholder’s meetin ...